Promoter analysis of epigenetically controlled genes in bladder cancer

Genes Chromosomes and Cancer

Volumn 47, Issue 5, 2008, Pages 368-378

  Veerla, Srinivas ^a   Panagopoulos, Ioannis ^a   Jin, Yuesheng ^a   Lindgren, David ^a   Höglund, Mattias ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' CYTIDINE; CYTIDINE DERIVATIVE; DNA FRAGMENT; UNCLASSIFIED DRUG; ZEBULARINE;

ANALYTIC METHOD; AQP11 GENE; ARTICLE; BINDING SITE; BLADDER CANCER; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; FIBROBLAST GROWTH FACTOR 18 GENE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENOMICS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; NUPR1 GENE; PRIORITY JOURNAL; PROMOTER REGION; STROMELYSIN 3 GENE; TIMP 1TISSUE INHIBITOR OF METALLOPROTEINASE 1 GENE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR TYPE 1 GENE; UBXD2 GENE; UPREGULATION;

BASE SEQUENCE; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; DNA PRIMERS; EPIGENESIS, GENETIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); URINARY BLADDER NEOPLASMS;

EID: 41349113351     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20542     Document Type: Article

References (44)

1. Bakkar AA, Wallerand H, Radvanyi F, Lahaye JB, Pissard S, Lecerf L, Kouyoumdjian JC, Abbou CC, Pairon JC, Jaurand MC, Thiery JP, Chopin DK, de Medina SG. 2003. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63:8108-8112.
2. Ballestar E, Wolffe AP. 2001. Methyl-CpG-binding proteins. Target-ing specific gene repression. Eur J Biochem 268:1-6.
3. Baylin SB, Herman JG. 2000. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends Genet 16:168-174.
4. Bell AC, Felsenfeld G. 2000. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405:482-485.
5. Bestor TH, Gundersen G, Kolsto AB, Prydz H. 1992. CpG islands in mammalian gene promoters are inherently resistant to de novo methylation. Genet Anal Technol Appl 9:48-53.
6. Bird A. 2002. DNA methylation patterns and epigenetic memory. Genes Dev 16:6-21.
7. Bird AP. 1986. CpG-rich islands and the function of DNA methylation. Nature 321:209-213.
8. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F. 1999. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23:18-20.
9. Cheng JC, Weisenberger DJ, Gonzales EA, Liang G, Xu GL, Hu YG, Marquez VE, Jones PA. 2004. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol Cell Biol 24:1270-1278.
10. Christoph F, Kempkensteffen C, Weikert S, Kollermann J, Krause H, Miller K, Schostak M, Schrader M. 2006. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Br J Cancer 95:1701-1707.
11. Cox GS, Gutkin DW, Haas MJ, Cosgrove DE. 1998. Isolation of an Alu repetitive DNA binding protein and effect of CpG methylation on binding to its recognition sequence. Biochim Biophys Acta 1396:67-87.
12. Davidson D, Blanc A, Filion D, Wang H, Plut P, Pfeffer G, Buschmann MD, Henderson JE. 2005. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J Biol Chem 280:20509-20515.
13. De Larco JE, Wuertz BR, Yee D, Rickert BL, Furcht LT. 2003. Atypical methylation of the interleukin-8 gene correlates strongly with the metastatic potential of breast carcinoma cells. Proc Natl Acad Sci USA 100:13988-13993.
14. Fatemi M, Wade PA. 2006. MBD family proteins: Reading the epigenetic code. J Cell Sci 119:3033-3037.
15. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. 2000. CTCF mediates methylation-sensitive enhancerblocking activity at the H19/Igf2 locus. Nature 405:486-489.
16. Hoffmann MJ, Florl AR, Seifert HH, Schulz WA. 2005. Multiple mechanisms downregulate CDKN1C in human bladder cancer. Int J Cancer 114:406-413.
17. Hoglund M, Sall T, Heim S, Mitelman F, Mandahl N, Fadl-Elmula I. 2001. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 61:8241-8246.
18. Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD, Fodstad O. 2006. Com-1/p8 acts as a putative tumour suppressor in prostate cancer. Int J Mol Med 18:981-986.
19. Jones PA. 2002. DNA methylation and cancer. Oncogene 21:5358-5360.
20. Jones PA, Laird PW. 1999. Cancer epigenetics comes of age. Nat Genet 21:163-167.
21. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. 1998. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187-191.
22. Kel AE, Gossling E, Renter I, Cheremushkin E, Kel-Margoulis OV, Wingender E. 2003. MATCH: A tool for searching transcription factor binding sites in DNA sequences. Nucleic Acids Res 31:3576-3579.
23. Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, Kakiuchi H, Kusano M, Issa JP, Tokino T, Imai K. 2002. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 21:2741-2749.
24. Kim WJ, Kim EJ, Jeong P, Quan C, Kim J, Li QL, Yang JO, Ito Y, Bae SC. 2005. RUNX3 inaetivation by point mutations and aberrant DNA methylation in bladder tumors. Cancer Res 65:9347-9354.
25. Klose RJ, Sarraf SA, Schmiedeberg L, McDermett SM, Stancheva I, Bird AP. 2005. DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent to mcthyl-CpG. Mol Cell 19:667-678.
26. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM. 2000. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem 275:31805-31812.
27. Mikovits JA, Young HA, Vertino P, Issa JP, Pitha PM, Turcoski-Corrales S, Taub DD, Petrow CL, Baylin SB, Ruscetti FW. 1998. Infection with human immunodeficiency virus type 1 upregulates DNA methyltransferase, resulting in de novo methylation of the gamma interferon (IFN-gamma) promoter and subsequent down-regulation of IFN-gamma production. Mol Cell Biol 18:5166-5177.
28. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. 1998. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389.
29. Niesen MI, Osborne AR, Yang H, Rastogi S, Chellappan S, Cheng JQ, Boss JM, Blanck G. 2005. Activation of a methylated promoter mediated by a sequence-specific DNA-binding protein, RFX. J Biol Chem 280:38914-38922.
30. Ning S, Huye LR, Pagano JS. 2005. Regulation of the transcriptional activity of the IRF7 promoter by a pathway independent of interferon signaling. J Biol Chem 280:12262-12270.
31. Nishimori S, Tanaka Y, Chiba T, Fujii M, Imamura T, Miyazono K, Ogasawara T, Kawaguchi H, Igarashi T, Fujita T, Tanaka K, Toyoshima H. 2001. Smad-mediated transcription is required for transforming growth factor-beta 1-induced p57(Kip2) proteolysis in osteoblastic cells. J Biol Chem 276:10700-10705.
32. Oka M, Meacham AM, Hamazaki T, Rodic N, Chang LJ, Terada N. 2005. De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2′-deoxycytidine. Oncogene 24:3091-3099.
33. Okano M, Bell DW, Haber DA, Li E. 1999. DNA methyltransferascs Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-257.
34. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R. 2000. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci USA 97:5237-5242.
35. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg A. Peterson C. 2002. BioArray Software environment (BASE): A platform for comprehensive management and analysis of microarray data. Genome Biol 3:SOFTWARE0003.
36. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N. 1998. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 441:106-110.
37. Scandura JM, Boccuni P, Massague J, Nimer SD. 2004. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc Natl Acad Sci USA 101:15231-15236.
38. Shen L, Toyota M, Kondo Y, Obata T, Daniel S, Pierce S, Imai K, Kantarjian HM, Issa JP, Garcia-Manero G. 2003. Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101:4131-4136.
39. Spruck CH, III, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmutte C, Yang AS, Cote R, Dubeau L, Nichols PW, Hermann GG, Steven K, Horn T, Skinner DG, Jones PA. 1994. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784-788.
40. Takai D, Jones PA. 2002. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99:3740-3745.
41. Unoki M, Nakamura Y. 2003. Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity. FEBS Lett 554:67-72.
42. Warnecke PM, Stirzaker C, Song J, Grunau C, Melki JR, Clark SJ. 2002. Identification and resolution of artifacts in bisulfite sequencing. Methods 27:101-107.
43. Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, Schubeler D. 2007. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet 39:457-466.
44. Zhou L, Cheng X, Connolly BA, Dickman MJ, Hurd PJ, Hornby DP. 2002. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J Mol Biol 321:591-599.